NL300258I2 - Farmaceutische samenstelling voor toepassing in debehandeling van. - Google Patents

Farmaceutische samenstelling voor toepassing in debehandeling van.

Info

Publication number
NL300258I2
NL300258I2 NL300258C NL300258C NL300258I2 NL 300258 I2 NL300258 I2 NL 300258I2 NL 300258 C NL300258 C NL 300258C NL 300258 C NL300258 C NL 300258C NL 300258 I2 NL300258 I2 NL 300258I2
Authority
NL
Netherlands
Prior art keywords
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
NL300258C
Other languages
English (en)
Other versions
NL300258I1 (nl
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15563926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300258(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NL300258I1 publication Critical patent/NL300258I1/nl
Publication of NL300258I2 publication Critical patent/NL300258I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
NL300258C 1995-06-20 2007-01-25 Farmaceutische samenstelling voor toepassing in debehandeling van. NL300258I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15350095 1995-06-20
EP96304570A EP0749751A3 (en) 1995-06-20 1996-06-20 Pharmaceutical composition for use in the treatment of diabetes

Publications (2)

Publication Number Publication Date
NL300258I1 NL300258I1 (nl) 2007-04-02
NL300258I2 true NL300258I2 (nl) 2007-05-01

Family

ID=15563926

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300258C NL300258I2 (nl) 1995-06-20 2007-01-25 Farmaceutische samenstelling voor toepassing in debehandeling van.
NL300432C NL300432I2 (en) 1995-06-20 2010-01-15 Pharmaceutical composition comprising pioglitazoneand glimepiride for use in treatment of diabetes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL300432C NL300432I2 (en) 1995-06-20 2010-01-15 Pharmaceutical composition comprising pioglitazoneand glimepiride for use in treatment of diabetes.

Country Status (26)

Country Link
US (44) US5952356A (nl)
EP (6) EP1764110A1 (nl)
JP (3) JP3148973B2 (nl)
KR (3) KR970000233A (nl)
CN (3) CN1212117C (nl)
AR (4) AR005641A1 (nl)
AT (2) ATE256463T1 (nl)
CA (3) CA2533845C (nl)
CY (4) CY2424B1 (nl)
CZ (2) CZ291624B6 (nl)
DE (4) DE69631157T2 (nl)
DK (2) DK0861666T3 (nl)
ES (2) ES2327383T5 (nl)
FR (1) FR09C0055I2 (nl)
HK (2) HK1010484A1 (nl)
HU (1) HUP9601698A3 (nl)
LU (2) LU91298I2 (nl)
MX (1) MX9602399A (nl)
MY (1) MY127530A (nl)
NL (2) NL300258I2 (nl)
NO (5) NO313226B1 (nl)
PT (2) PT861666E (nl)
RU (5) RU2198682C2 (nl)
SK (2) SK287287B6 (nl)
TW (2) TW438587B (nl)
ZA (1) ZA965190B (nl)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
KR19990036290A (ko) 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
PL193365B1 (pl) 1996-04-05 2007-02-28 Takeda Pharmaceutical Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz zastosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
KR100540618B1 (ko) 1996-07-15 2006-01-12 상꾜 가부시키가이샤 의약 조성물
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
SI0996444T1 (sl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Zdravljenje diabetesa s tiazolidindionom in metforminom
TR199903072T2 (xx) * 1997-06-18 2000-07-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve alfa-glukosidaz ile tedavisi.
AU783539B2 (en) * 1997-06-18 2005-11-10 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133137A (en) * 1997-06-18 2004-02-08 Smithkline Beecham Plc Pharmaceutical preparations containing 5 - [4 - (-2N) methyl - N - (2 - pyridyl) amino) ethoxy] benzyl] thiazolidine - 2, 4 deion and sulfonyl aura
AU778947B2 (en) * 1997-06-18 2004-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
AU782419B2 (en) * 1997-07-18 2005-07-28 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
WO1999020277A1 (fr) * 1997-10-20 1999-04-29 Dainippon Pharmaceutical Co., Ltd. Composition medicamenteuse a dissolution rapide
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AR019727A1 (es) 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
ES2206868T3 (es) 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
JP2002528500A (ja) * 1998-10-29 2002-09-03 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム チアゾリジンジオン誘導体の早期分娩または授乳期間における子宮収縮を予防するための使用
AU768994B2 (en) * 1998-11-12 2004-01-15 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AP1692A (en) * 1998-11-12 2006-12-12 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
CZ20012353A3 (cs) * 1998-12-24 2001-12-12 Metabasis Therapeutics, Inc. Farmaceutický prostředek obsahující kombinaci inhibitoru FBPázy a senzibilizátoru insulinu
CA2361303C (en) * 1999-01-29 2007-11-20 Takeda Chemical Industries, Ltd. Punch for preparing tablets
JP4799720B2 (ja) * 1999-01-29 2011-10-26 武田薬品工業株式会社 コーティング処理を施した打錠用杵
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6410802B1 (en) * 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
JP2000355550A (ja) * 1999-04-14 2000-12-26 Takeda Chem Ind Ltd ケトーシス改善剤
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AR023568A1 (es) * 1999-04-23 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una forma polimorfica de sal de acido maleico derivado de tiazolidina-2,4-diona
GB9910693D0 (en) * 1999-05-07 1999-07-07 Univ Liverpool A compound for use in medicine
US6214842B1 (en) * 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
US6380191B1 (en) * 1999-06-18 2002-04-30 Merck & Co. Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
AU5760900A (en) * 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU779730B2 (en) * 1999-06-30 2005-02-10 Amgen, Inc. Compounds for the modulation of PPARgamma activity
ES2437103T3 (es) * 1999-06-30 2014-01-08 Amgen Inc. Compuestos para la modulacion de la actividad de PPAR gamma
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7169407B1 (en) * 1999-10-06 2007-01-30 Toshio Miyata Carbonyl stress-decreasing agent
WO2001026639A2 (en) * 1999-10-08 2001-04-19 Novartis Ag Pharmaceutical composition of ateglinide and another antidiabeticagent
US6274622B1 (en) * 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CN1450902A (zh) 1999-11-03 2003-10-22 布里斯托尔-迈尔斯斯奎布公司 包含二甲双胍和格列本脲组合的药用组合物
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
AU2001229601A1 (en) * 2000-01-24 2001-07-31 Inotek Corporation Method and composition for modulating an immune response
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
CA2401356A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6451342B2 (en) 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6939362B2 (en) * 2001-11-27 2005-09-06 Advanced Cardiovascular Systems, Inc. Offset proximal cage for embolic filtering devices
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2002030425A1 (fr) * 2000-10-12 2002-04-18 Nissan Chemical Industries, Ltd. Medicaments pour la prevention ou le traitement de complications du diabete
US6506203B1 (en) 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
EP1236720B1 (en) 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
US20040110693A1 (en) * 2001-03-02 2004-06-10 Friedrich Trepel Agent for treating diabetes mellitus
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
JP2004528319A (ja) 2001-03-30 2004-09-16 ファイザー・プロダクツ・インク ピリダジノンアルドースレダクダーゼ阻害物質
CN1499971A (zh) * 2001-04-03 2004-05-26 ֮����ҩ��ʽ���� 芳基乙烯磺酰胺衍生物的新用途
PT1377276E (pt) * 2001-04-10 2011-12-30 Sun Pharma Advanced Res Co Ltd Composição de libertação temporizada por pulso
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
AU2001273310B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. A core formulation
AU2001273289B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
AU2003235120A1 (en) * 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Screening method
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
CA2494281A1 (en) 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CN100544717C (zh) 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
IN192749B (nl) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
US7976853B2 (en) * 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
WO2004089918A1 (ja) * 2003-04-09 2004-10-21 Japan Tobacco Inc. 複素芳香５員環化合物及びその医薬用途
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
WO2004096278A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited アディポネクチン産生増強剤
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
JP2007502847A (ja) * 2003-05-13 2007-02-15 シントン・ベスローテン・フェンノートシャップ チアゾリジンジオン誘導体およびその化合物を製造する方法
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
AU2004250994B2 (en) * 2003-06-27 2010-12-02 Dr. Reddy's Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20070032404A1 (en) * 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2008500955A (ja) * 2003-10-27 2008-01-17 イノディア インコーポレイテッド 糖尿病の治療に使用するための方法及び組成物
ZA200602056B (en) * 2003-10-31 2007-05-30 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
US7360069B2 (en) * 2004-01-13 2008-04-15 Hewlett-Packard Development Company, L.P. Systems and methods for executing across at least one memory barrier employing speculative fills
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
WO2005074909A1 (ja) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. 併用医薬
WO2005080387A2 (en) * 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP2248531A1 (en) * 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
CN101432004A (zh) * 2004-09-14 2009-05-13 伊利舍医药品公司 用于控制的碳水化合物消化的联合治疗
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
JP2009500401A (ja) * 2005-07-07 2009-01-08 ポステック ファンデーション 糖吸収調節剤及び薬学的組成物
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
MX2008001063A (es) * 2005-07-22 2008-03-19 Procter & Gamble Composiciones para reducir la incidencia de arritmia inducida por farmacos.
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
GEP20115245B (en) 2005-12-22 2011-06-27 Takeda Pharmaceutical Solid preparation
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007105730A1 (ja) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. インスリン抵抗性改善剤
JP5269758B2 (ja) 2006-03-16 2013-08-21 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体
US8338480B2 (en) * 2006-03-31 2012-12-25 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
ATE523474T1 (de) * 2006-04-11 2011-09-15 Sorbwater Technology As Verfahren zur entfernung von materialien aus einem flüssigkeitsstrom
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
US7752724B2 (en) * 2006-06-27 2010-07-13 Lumino, Inc. Method of cutting blinds
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
WO2008091624A2 (en) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
MY147596A (en) * 2007-02-01 2012-12-31 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
EP3053440B1 (en) 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
PT2489731E (pt) 2007-07-26 2014-09-15 Amgen Inc Enzimas aciltransferase de lecitina-colesterol modificadas
JP5371988B2 (ja) * 2007-09-14 2013-12-18 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧を処置するためのチアゾリジンジオン類似体
JPWO2009038107A1 (ja) * 2007-09-21 2011-01-06 キッセイ薬品工業株式会社 ２型糖尿病治療用の組合せ医薬
WO2009073627A1 (en) * 2007-11-30 2009-06-11 The Research Foundation Of State University Of New York Metabolic fuel switching biomarker
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN104805198B (zh) * 2008-08-12 2019-04-26 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CA2754901A1 (en) 2009-03-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20110038848A1 (en) 2009-08-12 2011-02-17 Melaleuca, Inc. Dietary supplement compositions for cardiovascular health
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
US8575177B2 (en) * 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
MX2012006725A (es) * 2009-12-15 2012-06-28 Metabolic Solutions Dev Co Llc Sales de tiazolidinadiona reductoras de receptores activados por proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
MX2012006730A (es) * 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
JP2013523819A (ja) * 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
RU2526153C2 (ru) * 2010-07-15 2014-08-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
UA114704C2 (uk) 2011-01-10 2017-07-25 Зінфандел Фармасьютікалз, Інк. Способи та лікарські засоби для лікування хвороби альцгеймера
EP2665477B1 (en) * 2011-01-20 2015-09-09 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
RU2572706C1 (ru) * 2014-06-30 2016-01-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
US20190350907A1 (en) 2017-01-16 2019-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
WO2019241576A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
CN112869173A (zh) * 2021-01-18 2021-06-01 广州富诺营养科技有限公司 一种复合维生素矿物质制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU598366B2 (en) 1987-03-20 1990-06-21 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4895862A (en) 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
US5260275A (en) 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2686861B2 (ja) * 1991-03-30 1997-12-08 キッセイ薬品工業株式会社 新規なベンジリデンコハク酸誘導体
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH07316144A (ja) * 1994-03-29 1995-12-05 Sankyo Co Ltd ジフェニルメチルピペラジン誘導体
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6001049A (en) * 1998-02-12 1999-12-14 Frey; Mark P. Light weight exercise apparatus

Also Published As

Publication number Publication date
US6911459B2 (en) 2005-06-28
NO2007001I2 (no) 2011-03-14
MY127530A (en) 2006-12-29
AU5603496A (en) 1997-01-09
KR20070081135A (ko) 2007-08-16
SK287351B6 (sk) 2010-08-09
JPH0967271A (ja) 1997-03-11
AU723097B2 (en) 2000-08-17
JP4809806B2 (ja) 2011-11-09
HK1010484A1 (en) 1999-06-25
US6150383A (en) 2000-11-21
EP1174135B1 (en) 2009-08-05
US6166042A (en) 2000-12-26
ES2327383T3 (es) 2009-10-29
NO20004345L (no) 1996-12-23
US7842706B2 (en) 2010-11-30
KR20080005162A (ko) 2008-01-10
RU2286148C2 (ru) 2006-10-27
NO2007007I1 (no) 2007-06-18
US6172090B1 (en) 2001-01-09
CY2007001I2 (el) 2009-11-04
US6218409B1 (en) 2001-04-17
US6121294A (en) 2000-09-19
US20030216443A1 (en) 2003-11-20
US6211206B1 (en) 2001-04-03
US6274605B1 (en) 2001-08-14
NO20021172L (no) 1996-12-23
RU2003130978A (ru) 2005-04-20
SK287287B6 (sk) 2010-05-07
DE69631157T2 (de) 2004-09-09
DE69637988D1 (de) 2009-09-17
DE69631157D1 (de) 2004-01-29
CY2424B1 (en) 2004-11-12
US6133295A (en) 2000-10-17
AR005641A1 (es) 1999-07-14
EP1174135A2 (en) 2002-01-23
CY2009018I1 (el) 2010-07-28
US6329404B1 (en) 2001-12-11
EP0749751A3 (en) 1997-04-16
US20110034518A1 (en) 2011-02-10
CY2608B2 (en) 2010-04-28
MX9602399A (es) 1997-02-28
CA2531834C (en) 2006-12-05
NO314065B1 (no) 2003-01-27
AR065389A2 (es) 2009-06-03
US6080765A (en) 2000-06-27
US20020123512A1 (en) 2002-09-05
CN1530105A (zh) 2004-09-22
ES2212208T3 (es) 2004-07-16
US6169100B1 (en) 2001-01-02
DE122007000002I1 (de) 2012-03-08
HUP9601698A3 (en) 2000-09-28
ATE256463T1 (de) 2004-01-15
DK1174135T3 (da) 2009-12-07
US6172089B1 (en) 2001-01-09
NO20021172D0 (no) 2002-03-08
US20090246232A1 (en) 2009-10-01
CY2009018I2 (el) 2010-07-28
NL300258I1 (nl) 2007-04-02
CN1145783A (zh) 1997-03-26
HK1041203B (zh) 2009-09-25
US6251924B1 (en) 2001-06-26
RU2223760C2 (ru) 2004-02-20
US20020128289A1 (en) 2002-09-12
EP1174135B2 (en) 2016-09-14
TWI238064B (en) 2005-08-21
HUP9601698A2 (hu) 1997-05-28
AR061195A2 (es) 2008-08-13
US6103742A (en) 2000-08-15
TW438587B (en) 2001-06-07
NO20004345D0 (no) 2000-09-01
US7538125B2 (en) 2009-05-26
EP2289556A3 (en) 2011-03-09
NO313226B1 (no) 2002-09-02
HK1041203A1 (en) 2002-07-05
US6225326B1 (en) 2001-05-01
CA2531834A1 (en) 1996-12-21
HU9601698D0 (en) 1996-08-28
US6384062B1 (en) 2002-05-07
US6174904B1 (en) 2001-01-16
JP3973280B2 (ja) 2007-09-12
NO2007007I2 (no) 2009-10-05
NL300432I2 (en) 2010-04-01
US20050054685A1 (en) 2005-03-10
US6303640B1 (en) 2001-10-16
CN1289082C (zh) 2006-12-13
NO2007001I1 (no) 2007-01-29
FR09C0055I2 (fr) 2010-06-11
EP1174135B9 (en) 2009-12-16
US6211205B1 (en) 2001-04-03
CY2007001I1 (el) 2009-11-04
EP2289556A2 (en) 2011-03-02
RU2198682C2 (ru) 2003-02-20
US6150384A (en) 2000-11-21
US6599923B2 (en) 2003-07-29
EP2292268A1 (en) 2011-03-09
US20020002186A1 (en) 2002-01-03
CA2179584C (en) 2007-04-24
US6232330B1 (en) 2001-05-15
CA2179584A1 (en) 1996-12-21
US20040266830A1 (en) 2004-12-30
ES2327383T5 (es) 2017-03-13
EP0861666A2 (en) 1998-09-02
DE122007000002I2 (de) 2012-03-08
LU91606I2 (fr) 2009-11-09
NO317341B1 (no) 2004-10-11
CZ291624B6 (cs) 2003-04-16
LU91298I2 (fr) 2007-02-20
US6133293A (en) 2000-10-17
US20070203198A1 (en) 2007-08-30
JP3148973B2 (ja) 2001-03-26
EP1174135A3 (en) 2002-06-19
US6211207B1 (en) 2001-04-03
US6277869B1 (en) 2001-08-21
US6169099B1 (en) 2001-01-02
US6156773A (en) 2000-12-05
US6271243B1 (en) 2001-08-07
CZ181196A3 (en) 1997-01-15
CA2533845A1 (en) 1996-12-21
DE122009000064I1 (de) 2011-12-01
EP1764110A1 (en) 2007-03-21
FR09C0055I1 (nl) 2009-04-12
CZ292093B6 (cs) 2003-07-16
JP2007191494A (ja) 2007-08-02
US6288090B1 (en) 2001-09-11
KR970000233A (ko) 1997-01-21
CN1530106A (zh) 2004-09-22
US20020042434A1 (en) 2002-04-11
EP0749751A2 (en) 1996-12-27
SK79496A3 (en) 1997-01-08
US7144900B2 (en) 2006-12-05
US5952356A (en) 1999-09-14
EP0861666B1 (en) 2003-12-17
AR091289A2 (es) 2015-01-28
US6121295A (en) 2000-09-19
PT1174135E (pt) 2009-08-31
US6239153B1 (en) 2001-05-29
CA2533845C (en) 2012-10-09
RU2327455C2 (ru) 2008-06-27
US6166043A (en) 2000-12-26
NO962606L (no) 1996-12-23
DK0861666T3 (da) 2004-03-08
RU2323004C2 (ru) 2008-04-27
US6214848B1 (en) 2001-04-10
CN1212117C (zh) 2005-07-27
EP0861666A3 (en) 1999-02-10
ZA965190B (en) 1997-12-19
NO962606D0 (no) 1996-06-19
ATE438397T1 (de) 2009-08-15
US6323225B1 (en) 2001-11-27
JPH10167986A (ja) 1998-06-23
NL300432I1 (en) 2010-03-01
US5965584A (en) 1999-10-12
PT861666E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
NL300258I2 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van.
NL1003813A1 (nl) Inrichting voor de behandeling van luchtwegobstructies.
NL1004155A1 (nl) Antiparasitaire samenstelling voor de behandeling en de bescherming van gezelschapsdieren.
BR9706897B1 (pt) forma de dosagem farmacêutica.
BR9713237B1 (pt) comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo.
NL194664B (nl) Farmaceutische samenstelling voor het genezen van tumorachtige ziekten.
BR9506119A (pt) Composição farmacêutica e forma de dosagem farmacêutica unitária
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NL194442B (nl) Werkwijze voor de bereiding van organopolysiloxanen.
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
NO990225D0 (no) Medikamenter for behandling av hyperfosfatemi
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DZ1926A1 (fr) Formulations pharmaceutiques.
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
NO982562D0 (no) Sammensetning for behandling av smerte
NO973341D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for vasodilatorisk behandling eller profylakse
ZA97902B (en) Biologically active ureido derivatives useful in the treatment of multiple sclerosis.
NL194693B (nl) Werkwijze voor het bereiden van medicinale preparaten voor het behandelen van diabetes.
BR9505394A (pt) Composição para pinturas artísticas corporal no corpo humano